# Krystal Biotech, Inc.

> Krystal Biotech is a Pittsburgh-based commercial-stage biotechnology company that pioneered redosable, off-the-shelf gene therapy delivered directly to the body. Its lead product VYJUVEK became the first FDA-approved topical and redosable gene therapy in 2023, treating the rare skin disease dystrophic epidermolysis bullosa. Built on a proprietary HSV-1 vector platform (STAR-D), the company runs its own GMP manufacturing and is extending the same delivery technology into respiratory disease, oncology, ophthalmology and aesthetics.

- **Founded:** 2016
- **Headquarters:** Pittsburgh, Pennsylvania, United States
- **Founders:** Krish S. Krishnan (Co-Founder, Chairman & CEO), Suma M. Krishnan (Co-Founder & President, Research & Development)
- **Team size:** ~280 employees
- **Products:** VYJUVEK (beremagene geperpavec-svdt), STAR-D Platform, KB407, KB301, KB707
- **Notable:** VYJUVEK is the first FDA-approved topical gene therapy (2023)., First approved gene therapy to use HSV-1 as a delivery vector., First approved redosable gene therapy - designed for repeat administration.

## Products & services

- **VYJUVEK (beremagene geperpavec-svdt)** — First FDA-approved topical, redosable gene therapy for wounds in patients with dystrophic epidermolysis bullosa (DEB) with COL7A1 mutations. Delivers functional COL7A1 genes to skin cells using a modified HSV-1 vector.
- **STAR-D Platform** — Proprietary gene-delivery platform using an engineered, non-integrating HSV-1 vector with high payload capacity, broad cell tropism and immune evasion, enabling repeat dosing.
- **KB407** — Inhaled gene therapy for cystic fibrosis, delivering full-length CFTR; granted FDA platform technology designation.
- **KB301** — Aesthetic and dermatology candidate delivering type III collagen, in Phase 2 clinical development.
- **KB707** — Inhaled/intratumoral immunotherapy candidate for solid tumors including non-small cell lung cancer.
- **KB801 / KB803** — Ophthalmology candidates for neurotrophic keratitis and ocular complications of DEB.
- **KB408 / KB111 / KB801** — Earlier-stage programs for alpha-1 antitrypsin deficiency, Hailey-Hailey disease and other indications.

## Achievements

- VYJUVEK is the first FDA-approved topical gene therapy (2023).
- First approved gene therapy to use HSV-1 as a delivery vector.
- First approved redosable gene therapy - designed for repeat administration.
- First approved medicine for wounds caused by dystrophic epidermolysis bullosa.
- Grew to $290.5M revenue in its first full commercial year, up 473%.
- Built and operates its own GMP gene-therapy manufacturing facilities in Pittsburgh.
- Co-founder Suma Krishnan recognized by Forbes among leading self-made biotech founders.

## Latest updates

- **2026-01** — Reported preliminary 2025 results with 4Q VYJUVEK net revenue of roughly $106-107M and cumulative launch revenue over $846M; outlined 2026 objectives.
- **2025-07** — Forbes profiled co-founder Suma Krishnan and the company's rise to a multi-billion-dollar valuation.
- **2025-05** — Reported ~$88M VYJUVEK revenue in Q1 2025 and continued pipeline progress in cystic fibrosis, oncology and aesthetics.
- **2024-12** — Advanced pipeline programs KB407 (CF), KB301 (aesthetics), KB707 (oncology) and ophthalmology candidates.

## Links

- Website: https://krystalbio.com
- LinkedIn: http://www.linkedin.com/company/krystal-biotech-inc
- Twitter/X: https://twitter.com/KrystalBiotech

---

Profile page: https://yespress.io/krystal-biotech-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-14